Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-03-2016 | Original Article

Molecular response assessed by ⁶⁸Ga-DOTANOC and survival after ⁹⁰Y microsphere therapy in patients with liver metastases from neuroendocrine tumours

Authors: Luca Filippi, Francesco Scopinaro, Giuseppe Pelle, Roberto Cianni, Rita Salvatori, Orazio Schillaci, Oreste Bagni

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2016

Abstract

Purpose

We investigated the prognostic role of ⁶⁸Ga-DOTANOC in patients affected by hepatic metastases from neuroendocrine tumours (NET) undergoing ⁹⁰Y radioembolization (⁹⁰Y-RE).

Methods

A group of 15 consecutive patients with unresectable NET liver metastases underwent ⁶⁸Ga-DOTANOC PET at baseline and 6 weeks after ⁹⁰Y-RE. Molecular response was defined as a reduction of >50 % in the tumour-to-spleen ratio (ΔT/S). The patients were divided into two groups (responders with ΔT/S >50 % and nonresponders with ΔT/S <50 %) Patients were followed up by imaging and laboratory tests every 3 months until death or for at least 36 months following ⁹⁰Y-RE. Statistical analysis was performed to identify factors predicting overall survival (OS) and progression-free survival (PFS).

Results

A decrease in T/S ratio was seen in all patients on ⁶⁸Ga-DOTANOC PET scans performed after ⁹⁰Y-RE. Nine patients were classified as responders and six as nonresponders. The mean OS in all patients was 31.0 months. Responders had a significantly (p < 0.001) longer OS (mean 36.0 ± 2.5 months) and PFS (mean 29.7 ± 3.4 months) than nonresponders. In a multivariate analysis, none of the other examined variables including age, unilobar vs. bilobar locations, bilirubin levels, radiological response or the presence of extrahepatic disease significantly predicted patient outcome.

Conclusion

Molecular response assessed with ⁶⁸Ga-DOTANOC PET might be a useful predictor of survival in patients affected by NET liver metastases treated with ⁹⁰Y-RE.

Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist. 2005;10:123–31.PubMedCrossRef

Basuroy R, Srirajaskanthan R, Ramage JK. A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol. 2012;2012:819193. doi:10.1155/2012/819193.PubMedPubMedCentralCrossRef

O’Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol. 2005;19:585–94.PubMedCrossRef

Van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol. 2009;5:382–93.PubMedCrossRef

McStay MK, Maudgil D, Williams M, Tibballs JM, Watkinson AF, Caplin ME, et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology. 2005;237:718–26.PubMedCrossRef

Cianni R, Pelle G, Notarianni E, Saltarelli A, Rabuffi P, Bagni O, et al. Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. Eur Radiol. 2013;23:182–9.PubMedCrossRef

Rajekar H, Bogammana K, Stubbs RS. Selective internal radiation therapy for gastrointestinal neuroendocrine tumour liver metastases: a new and effective modality for treatment. Int J Hepatol. 2011;2011:404916. doi:10.4061/2011/404916.PubMedPubMedCentralCrossRef

Annunziata S, Treglia G, Caldarella C, Galiandro F. The role of 18F-FDG-PET and PET/CT in patients with colorectal liver metastases undergoing selective internal radiation therapy with yttrium-90: a first evidence-based review. ScientificWorldJournal. 2014;2014:879469. doi:10.1155/2014/879469.PubMedPubMedCentralCrossRef

Belhocine T, Foidart J, Rigo P, Najjar F, Thiry A, Quatresooz P, et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumors: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun. 2002;23:727–34.PubMedCrossRef

10.

Ambrosini V, Campana D, Tomassetti P, Fanti S. 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging. 2012;39:S52–60.PubMedCrossRef

11.

Koch W, Auernhammer CJ, Geisler J, Spitzweg C, Cyran CC, Ilhan H, et al. Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography. Mol Imaging. 2014;13:1–10.PubMed

12.

Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13–23.PubMedCrossRef

13.

Shaheen M, Hassanain M, Aljiffry M, Cabrera T, Chaudhury P, Simoneau E, et al. Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis. HPB (Oxford). 2012;14:60–6.CrossRef

14.

Bagni O, D'Arienzo M, Chiaramida P, Chiacchiararelli L, Cannas P, D’Agostini A, et al. 90Y-PET for the assessment of microsphere biodistribution after selective internal radiotherapy. Nucl Med Commun. 2012;33:198–204.PubMedCrossRef

15.

King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113:921–9.PubMedCrossRef

16.

Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15:e8–21.PubMedCrossRef

17.

Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271–9.PubMedCrossRef

18.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef

19.

Barnacle AM, McHugh K. Limitations with the Response Evaluation Criteria in Solid Tumors (RECIST) guidance in disseminated pediatric malignancy. Pediatr Blood Cancer. 2006;46:127–34.PubMedCrossRef

20.

Peker A, Çiçek O, Soydal Ç, Küçük NÖ, Bilgiç S. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. Diagn Interv Radiol. 2015;21:54–9.PubMedPubMedCentralCrossRef

21.

Herder WW, Kwekkeboom DJ, Valkema R, Feelders RA, van Aken MO, Lamberts SW, et al. Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest. 2005;28:132–6.PubMed

22.

Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med. 1995;36:542–9.PubMed

23.

Kjaer A, Knigge U. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. Scand J Gastroenterol. 2015;50:740–7.PubMedPubMedCentral

24.

Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982–93.PubMedCrossRef

25.

Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J Med Imaging Radiat Oncol. 2012;56:40–7.PubMedCrossRef

26.

Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:1271–7.PubMedCrossRef

27.

Sharma P, Arora S, Dhull VS, Naswa N, Kumar R, Ammini AC, et al. Evaluation of (68)Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors. Abdom Imaging. 2015;40:299–309.PubMedCrossRef

28.

Ezziddin S, Meyer C, Kahancova S, Haslerud T, Willinek W, Wilhelm K, et al. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. J Nucl Med. 2012;53:1663–9.PubMedCrossRef

29.

Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50:1427–34.PubMedCrossRef

30.

Kwee TC, Cheng G, Lam MG, Basu S, Alavi A. SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions. Eur J Nucl Med Mol Imaging. 2013;40:1475–7.PubMedCrossRef

31.

Haug AR, Auernhammer CJ, Wängler B, Schmidt GP, Uebleis C, Göke B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med. 2010;5:1349–56.CrossRef

32.

Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, et al. SUV of 68GaDOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol Imaging Biol. 2015;17:313–8.PubMedCrossRef

33.

Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431–8.PubMedCrossRef

34.

Bagni O, Filippi L, Schillaci O. 18F-FDG PET-derived parameters as prognostic indices in hepatic malignancies after 90Y radioembolization: is there a role? Eur J Nucl Med Mol Imaging. 2015;42:367–9.PubMedCrossRef

35.

Luboldt W, Hartmann H, Wiedemann B, Zöphel K, Luboldt HJ. Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga-DOTATOC PET/CT using the example of somatostatin receptor radionuclide therapy. Mol Imaging. 2010;9:351–8.PubMed

Title: Molecular response assessed by 68Ga-DOTANOC and survival after 90Y microsphere therapy in patients with liver metastases from neuroendocrine tumours
Authors: Luca Filippi
Francesco Scopinaro
Giuseppe Pelle
Roberto Cianni
Rita Salvatori
Orazio Schillaci
Oreste Bagni
Publication date: 01-03-2016
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-015-3178-3

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Molecular response assessed by ⁶⁸Ga-DOTANOC and survival after ⁹⁰Y microsphere therapy in patients with liver metastases from neuroendocrine tumours

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2016

Reply to: “Comments on Kristensen et al.: Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients”

Radiopharmaceuticals in paraganglioma imaging: too many members on board?

Nuclear medicine training in the European Union: 2015 update

Reply to the letter of Zattoni et al.

Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting

Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT